Post-COVID-19 ConditionNCT07332338
Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition
A study testing REGENECYTE® in people with Post-COVID-19 Condition and Post-COVID Condition, run by StemCyte, Inc. at 2 sites in United States.
Trial summary
REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome
- What is being tested?
- REGENECYTE®
- How many people
- Not given
- Where
- 2 sitesUnited States
- Study dates
- Start not givento not given
- Phase
- Expanded access
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Who may be able to join
- Male or female aged ≥ 18
- With post-COVID condition
- Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR (polyermerase chain reaction) or antigen test)
- Not eligible for participation in any ongoing clinical trials of post-COVID condition with REGENECYTE
- Able to provide signed informed consent (by the subject or his/her legally authorized representative)
- Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent
Who cannot join
- Neurological disorders prior to COVID-19 diagnosis
- With pre-existing terminal illness
- With known immune disease
- Is pregnant or breastfeeding
- Is currently participating in another investigational study or has been taking any other investigational product (IP) within the last 4 weeks before screening
- Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period
- Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases
- Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters
Trial locations and contacts
2 sites in 1 country.
United States2 sites
- Available
D&H National Research Center #1
Miami, Florida, 33169
Joseph Durandis, M.D., 786-375-6210, drjdurandis@nrcinc.com
Joseph Durandis, M.D.
- Available
Myrak Research Center Inc.
Miami Lakes, Florida, 33014
Danay Gonzalez, 305-825-1400, dgonzalez@myrakresearchcenter.com
Aristides Canalejo Martinez, M.D.
About this study
Official title: Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion for Patients With Post-COVID Condition
REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.
Read the detailed description
A total of 30 subjects with post-COVID will be enrolled.
- Conditions
- Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome, Long COVID, Chronic Fatigue, Chronic Fatigue Symptoms
- Being tested
- REGENECYTE®
- Keywords
- Long COVID, Post-COVID syndrome, Post-COVID condition, Umbilical cord blood, REGENECYTE, Post-COVID fatigue, Chronic fatigue symptoms, Fatigue post viral
- Medical subject headings
- Post-Acute COVID-19 Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
REGENECYTE®Biological
HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Post-COVID-19 ConditionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- StemCyte, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07332338
- Sponsor's protocol ID
- SCUS001-EA1
- Status last verified
- Mar 2026
- First submitted
- 29 Dec 2025
- Last updated
- 23 Mar 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion for Patients With Post-COVID Condition
- ClinicalTrials.gov ID
- NCT07332338
- Acronym / sponsor ID
- SCUS001-EA1
- Conditions
- Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome, Long COVID, Chronic Fatigue, Chronic Fatigue Symptoms
- Keywords
- Long COVID, Post-COVID syndrome, Post-COVID condition, Umbilical cord blood, REGENECYTE, Post-COVID fatigue, Chronic fatigue symptoms, Fatigue post viral
- Study type
- Expanded access
- Recruitment status
- Available
- Lead sponsor
- StemCyte, Inc.Industry (pharma, biotech, devices)
- First posted
- 12 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.
Detailed description
A total of 30 subjects with post-COVID will be enrolled.
Study design
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Male or female aged ≥ 18
- With post-COVID condition
- Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR (polyermerase chain reaction) or antigen test)
- Not eligible for participation in any ongoing clinical trials of post-COVID condition with REGENECYTE
- Able to provide signed informed consent (by the subject or his/her legally authorized representative)
Key exclusion criteria (8 listed)
- Neurological disorders prior to COVID-19 diagnosis
- With pre-existing terminal illness
- With known immune disease
- Is pregnant or breastfeeding
- Is currently participating in another investigational study or has been taking any other investigational product (IP) within the last 4 weeks before screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| REGENECYTE®HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood) | Biological | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Mar 2026.
Related trials for Post-COVID-19 Condition
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Not yet recruitingPhase 3
The Study of Brave-LC LDN Treatment Trial
Post-acute COVID-19 Syndrome
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing REGENECYTE® in people with Post-COVID-19 Condition and Post-COVID Condition, run by StemCyte, Inc. at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Clinical Research Department (886-2-26013013 ext. 813, expandedaccess@stemcyte.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Mar 2026.